HyperRHO S/D Full Dose Indications/Uses

Pregnancy and Other Obstetric Conditions: HyperRHO S/D Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D) negative mother within 72 hours after birth of an Rh_o(D) positive infant, providing the following criteria are met: The mother must be Rh_o(D) negative and must not already be sensitized to the Rh_o(D) factor.
Her child must be Rh_o(D) positive, and should have a negative direct antiglobulin test (see Precautions).
If HyperRHO S/D Full Dose is administered antepartum, it is essential that the mother receive another dose of HyperRHO S/D Full Dose after delivery of an Rh_o(D) positive infant.
If the father can be determined to be Rh_o(D) negative, HyperRHO S/D Full Dose need not be given.
HyperRHO S/D Full Dose should be administered within 72 hours to all nonimmunized Rh_o(D) negative women who have undergone spontaneous or induced abortion, following ruptured tubal pregnancy, amniocentesis or abdominal trauma unless the blood group of the fetus or the father is known to be Rh_o(D) negative. If the fetal blood group cannot be determined, one must assume that it is Rh_o(D) positive, and HyperRHO S/D Full Dose should be administered to the mother.
Transfusion: HyperRHO S/D Full Dose may be used to prevent isoimmunization in Rh_o(D) negative individuals who have been transfused with Rh_o(D) positive red blood cells or blood components containing red blood cells.